Boothbay Fund Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-13,600
Closed -$1.89M 2489
2021
Q3
$1.89M Buy
+13,600
New +$1.7M 0.05% 471
2021
Q1
Sell
-124
Closed -$1.06M 2022
2020
Q4
$1.06M Buy
+124
New +$10.5K 0.04% 471
2020
Q3
Sell
-35
Closed -$256K 1391
2020
Q2
$256K Sell
35
-329
-90% -$17.5K 0.02% 742
2020
Q1
$1.24M Sell
364
-20
-5% -$914 0.1% 250
2019
Q4
$2.09M Sell
384
-287
-43% -$14.2K 0.18% 150
2019
Q3
$2.8M Sell
671
-178
-21% -$7.52K 0.26% 94
2019
Q2
$3.72M Buy
849
+412
+94% +$23.2K 0.34% 60
2019
Q1
$2.25M Buy
+437
New +$18.9K 0.22% 108
2018
Q2
Sell
-397
Closed -$1.02M 1012
2018
Q1
$1.02M Buy
397
+241
+154% +$7.21K 0.12% 173
2017
Q4
$421K Sell
156
-125
-44% -$3.44K 0.06% 319
2017
Q3
$1.05M Buy
+281
New +$8.52K 0.17% 140

Other funds holding BHVN

Boothbay Fund Management's BHVN Position: Q4 2022 in Review

Boothbay Fund Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 9,552 shares — an estimated $1.44M sold.

Boothbay Fund Management first reported a position in BHVN in Q1 2018 and held it in 6 quarters. The position peaked at $1.44M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Boothbay Fund Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 9,552 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $1.44M.
  • Boothbay Fund Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018 and held it in 6 quarters.
  • Boothbay Fund Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.44M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Boothbay Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.